Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NaviMed Capital is an active private equity and growth capital investment firm focused exclusively on the healthcare industry. It invests in fast-growing lower middle-market healthcare businesses across services, IT, hospital products, and distribution. The firm has over $850 million of assets under management and recently closed its third fund at $450 million. Its strategy centers on acquiring or recapitalizing profitable private companies with up to $10 million EBITDA and double-digit revenue growth. Recent exits include Argos Health, CenterPointe Behavioral Health System, The CM Group, Lighthouse Lab Services, Lucent Health, and Velocity Clinical Research. NaviMed partners with experienced management teams to scale businesses through expansion or acquisition. The team has created more than $11 billion of enterprise value across dozens of investments. As an investor rather than an operator or developer of drugs/devices/platforms itself, clinical results/pipeline are not applicable. Headquarters are in Arlington/Rosslyn VA/Washington DC area. Key people include co-founders Bijan Salehizadeh MD and Ryan Schwarz. Portfolio focus includes business process outsourcing for hospitals/providers and specialty healthcare service providers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NaviMed Capital.